CirChem AB

As of June 30, 2026, CirChem AB carries a market capitalization of 27.90M, placing it among publicly traded companies globally. Its enterprise value stands at 19.78M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, CirChem AB has 40.21M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 3.93, and the price-to-book ratio stands at 0.60.

These figures are as of June 30, 2026. The EV/Sales ratio of 2.75 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 19.78M versus a market cap of 27.90M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, CirChem AB maintains a current ratio of 0.97, meaning it holds 1.0x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, CirChem AB posted a negative return on equity (ROE) of -36.61, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -26.03, reflecting losses generated across the asset base. The company generates approximately 552,538.46 in revenue per employee across its workforce of 13.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 4.36 indicates how many times CirChem AB sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on October 22, 2026, CirChem AB's stock has declined approximately 62.28% over the past 52 weeks. The 50-day moving average sits at 0.58, while the 200-day moving average is 0.82.

Over the twelve months ended June 30, 2026, CirChem AB generated 7.18M in revenue and converted that into -18.13M in net income, yielding earnings per share of -0.45. EBITDA reached -15.84M, while operating income came in at -16.96M.

These figures are as of June 30, 2026. Total book value stands at 46.38M, with working capital of -496,000.00 providing operational flexibility.

CirChem AB produced -11.60M in operating cash flow over the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, CirChem AB posted a gross margin of 67.87, reflecting its pricing power and cost economics. The operating margin of -236.17 and net profit margin of -252.47 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -41.07: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -65.77, meaning CirChem AB raised more capital through share issuance and new debt than it returned via dividends and buybacks.

CirChem AB's most recent stock split took place on May 28, 2026 with a 437:445 split ratio.

As of June 30, 2026, CirChem AB has an Altman Z-Score of -0.23, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.